Initiative for adoption of legislation concerning legalization of cannabis products for medical use has been supported by companies manufacturing medicinal products or food supplements as well as the civil associations promoting and supporting cannabis use.

In public debates, representatives from all relevant institutions: Agency for medicines and medical devices of Republic of Macedonia, Pharmaceutical and Medical Faculties in Skopje, Key Opinion Leaders and doctors of different specialties, guests from abroad involved with this issue, representatives from pharmaceutical companies, pharmacists and other representatives from the health sectors participated.

The debates were interactive, including participation of civils seeking help for treatment of various diseases for themselves or their family members. They all stood together on side of legalization of cannabis use in medical purposes.

With the new legislation, a clear definition of permitted substances and concentrations succeeded. Products containing below 0.2% of psychotropic THC (delta-9-tetrahydrocannabinol) and CBD or other non-psychotropic cannabinoids (CBD, CBN, CBG) in higher concentrations, are categorized as borderline products meaning that they can be dispensed without prescription.

Such products are intended for preventive purposes, they are safe to use and can only have positive impact on the psycho-physical condition of the human body.